Clinical outcomes in a cohort of patients with cutaneous T-cell lymphoma and COVID-19

Runge, John S.; Bardhi, Redina; Yang, Xiaobo; Jairath, Neil; Wilcox, Ryan A.; Tsoi, L.C.; Tejasvi, Trilokraj

doi:10.1016/j.jdin.2022.04.008

Cited by 1 publication

(1 citation statement)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have evaluated risk factors for severe COVID-19 among patients with MF/SS, which included lymphopenia, chronic organ failure, Sezary syndrome, or active aggressive disease [11]. Moreover, initial reports indicate that clinical outcomes of patients with MF/SS that were infected with COVID-19 were not significantly different from the general population [12, 13]. However, most of these studies were conducted at the beginning of the pandemic and included only the SARS-CoV-2 Alpha variant and non-vaccinated patients.…”

Section: Introductionmentioning

confidence: 99%

Clinical Outcomes of COVID-19 in Mycosis Fungoides and Sezary Syndrome

Yurkovski¹,

Rokach²,

Melamed³

et al. 2023

Acta Haematol

View full text Add to dashboard Cite

Introduction: Haemato-oncologic patients are more susceptible to severe infections with SARS-CoV-2. We aimed to assess the clinical outcomes of SARS-CoV-2 infection among patients with Mycosis Fungoides and Sezary Syndrome (MF/SS). Methods: The data was retrieved from anonymized electronic medical records of Maccabi Healthcare Services (MHS), the second-largest healthcare organization in Israel. Patients diagnosed with MF/SS were included in the study. COVID-19 PCR, test results together with socio-demographic and clinical data were extracted and analyzed to evaluate the association of COVID-19 with clinical outcomes. Results: In the period of 2020-2022, 1472 MF/SS patients were included in the study. Among them, 768 (52%) had SARS-CoV-2 infection. The hospitalization rate was 2.9% and infection by the Delta variant was associated with the highest hospitalization rate (7.7%). The hospitalization rate was lower among fully vaccinated patients (p=0.032), but higher for patients older than 65 (p<0.001) and patients with SS (vs. MF) (p<0.001) or COPD (p=0.024) diagnosis. There was a tendency for decreased hospitalization among patients treated with nirmatrelvir + ritonavir within five days of infection, with a 79% risk reduction, although it was not statistically significant (p=0.164). Conclusion: Patients with MF/SS do not necessarily have worse COVID-19 outcomes compared to the general population.

show abstract

Section: Introductionmentioning

confidence: 99%